Service use: Number of participants hospitalised · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower service use: number of participants hospitalised compared with placebo/no treatment (high certainty).
1 finding from 1 review
Death due to suicide · schizophrenia
Maintenance treatment with antipsychotic drugs showed no clear difference in death: due to suicide compared with placebo/no treatment (low certainty).
1 finding from 1 review
QoL · schizophrenia
1 finding from 1 review
Employment · schizophrenia
Maintenance treatment with antipsychotic drugs showed no clear difference in number of participants in employment compared with placebo/no treatment (low certainty).
1 finding from 1 review
Social functioning · schizophrenia
1 finding from 1 review
Mental state: clinically important change in general mental state ‐ worsening psychosis · schizophrenia or related disorders
Modafinil showed no clear difference in mental state: clinically important change in general mental state ‐… compared with placebo (low certainty).
1 finding from 1 review
Cognitive function: average endpoint score** · schizophrenia or related disorders
1 finding from 1 review
Adverse effect/event(s) ‐ serious adverse events · schizophrenia or related disorders
It is very uncertain whether modafinil changes adverse effect/event(s) ‐ serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · schizophrenia or related disorders
It is very uncertain whether modafinil changes global state: clinically important change in global state compared with placebo (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia or related disorders
Modafinil showed no clear difference in leaving the study early ‐ for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · schizophrenia or related disorders
1 finding from 1 review
Hospital admissions · schizophrenia or related disorders
It is very uncertain whether modafinil changes service use: hospital admission compared with placebo (very low certainty).
1 finding from 1 review
Global state: any change in global state – unspecified problem necessitating change in dose or type of antipsychotics – medium term · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes global state: any change in global state – unspecified problem… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Cognitive functioning Clinically important change in cognitive functioning as defined by each study · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse events: gastrointestinal – dyspeptic symptoms – self‐assessed as at least 'moderate' · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes adverse events: gastrointestinal – dyspeptic symptoms –… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: change in hospital status – any change · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes service use: change in hospital status – any change compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group A: amino acids changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with placebo (very low certainty).
1 finding from 1 review